Elke De Wachter

Elke De Wachter

Auto-generated profile, based on publicly available information

Elke De Wachter

Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2010 in BMC Microbiology
Verified
Journal Article
Open access
PDF file
PDPieter Deschaght
Pieter Deschaght
PSPetra Schelstraete
Petra Schelstraete
GSGuido Lopes dos Santos Santiago
Guido Lopes dos Santos Santiago
LSLeen Van Simaey
Leen Van Simaey
FHFilomeen Haerynck
Filomeen Haerynck
FBFrans De Baets
Frans De Baets
Pseudomonas aeruginosa is the major respiratory pathogen causing severe lung infections among CF patients, leading to high morbidity and mortality. Once infection is established, early antibiotic treatment is able to postpone the transition to chronic lung infection. In order to optimize the early detection, we compared the sensitivity of microbiological culture and quantitative PCR (qPCR) for the detection of P. aeruginosa in respiratory samples of not chronically infected CF patients. In this national study, we followed CF patients during periods between 1 to 15 months. For a total of 852 samples, 729 (86%) remained P. aeruginosa negative by both culture and qPCR, whereas 89 samples (10%) were positive by both culture and qPCR. Twenty-six samples were negative by culture but positive by qPCR, and 10 samples were positive by culture but remained negative by qPCR. Five of the 26 patients with a culture negative, qPCR positive sample became later P. aeruginosa positive both by culture and qPCR. Based on the results of this study, it can be concluded that qPCR may have a predictive value for impending P. aeruginosa infection for only a limited number of patients.

22 February 2024 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
EWE De Wachter
E De Wachter
KBK De Boeck
K De Boeck
ISI Sermet-Gaudelus
I Sermet-Gaudelus
NSNj Simmonds
Nj Simmonds
AMAnne Munck
Anne Munck
CCC Castellani
C Castellani

22 April 2019 in Acta Clinica Belgica
Verified
Journal Article
Closed access
MSMasja Schmidt
Masja Schmidt
AWAmber Werbrouck
Amber Werbrouck
NVNick Verhaeghe
Nick Verhaeghe
EWElke De Wachter
Elke De Wachter
SSSteven Simoens
Steven Simoens
KPKoen Putman
Koen Putman
Objectives: The most cost-effective newborn screening strategy for cystic fibrosis (CF) for Flanders, Belgium, is unknown. The aim of this study was to assess the cost-effectiveness of four existing newborn screening strategies for CF: IRT-DNA (immunoreactive trypsinogen, cystic fibrosis transmembrane conductance regulator (CFTR) gene mutation analysis), IRT-PAP (pancreatitis-associated protein), IRT-PAP-DNA, and IRT-PAP-DNA-EGA (extended CFTR gene analysis). Methods: Using data from published literature, the cost-effectiveness of the screening strategies was calculated for a hypothetical cohort of 65,606 newborns in Flanders, Belgium. A healthcare payer perspective was used, and the direct medical costs associated with screening were taken into account. The robustness of the model outcomes was assessed in sensitivity analyses. Results: The IRT-PAP strategy was the most cost-effective strategy in terms of costs per CF case detected (€9314 per CF case detected). The IRT-DNA strategy was more costly (€13,966 per CF case detected), but with an expected sensitivity of 93.4% also the most effective strategy, and was expected to detect 2.2 more cases of CF than the IRT-PAP strategy. The incremental cost-effectiveness ratio of IRT-DNA vs. IRT-PAP was €54,180/extra CF case detected. The IRT-PAP-DNA strategy and the IRT-PAP-DNA-EGA strategy were both strongly dominated by the IRT-PAP strategy. Conclusion: The IRT-PAP strategy was the most cost-effective strategy in terms of costs per CF case detected. However, the strategy did not fulfil the European Cystic Fibrosis Society guidelines for sensitivity and positive predictive value. Therefore, the more costly and more effective IRT-DNA strategy may be the most appropriate newborn screening strategy for Flanders.

22 August 2017 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
EWE. De Wachter
E. De Wachter
MTM. Thomas
M. Thomas
SWS. S. Wanyama
S. S. Wanyama
SSS. Seneca
S. Seneca
AMA. Malfroot
A. Malfroot
CFTR2 provides clinical and functional information of the most common CFTR-mutations. Rare mutations (RMs) occur in only a few patients with limited reported clinical data. Their role in CF-disease liability is hardly documented. Belgian CF-Registry 2013 data were analyzed to identify CF with at least 1 RM (CF+RM). Clinical data and sweat chloride of CF+RM were compared to CF-controls, carrying 2 class 1 to 3 mutations (CFclassic). Disease severity was compared between both groups. To avoid bias in the comparison, transplanted patients were excluded from each group. Seventy-seven CF+RM were identified (77/1183 = 6.5%). Sixty-four different RM were detected, of which 21 had not been previously reported. All RMs, corresponding to HGVS (Human Genome Variation Society) nomenclature, were listed in supplementary data. Seven transplanted CF+RM were excluded for further analysis. CF+RM had higher age at diagnosis [median (IQR)] [3.7 y (0.3–18.3) vs. 0.3y (0.1–2,0) (p < 0.0001)], lower sweat chloride [96 mmol/L (64–107) vs. 104 mmol/L (97–115) (p < 0.0001)], higher FEV1%pred [77%pred (58–96) vs. 68%pred (48–86) (p = 0.017)], were less frequently pancreatic insufficient [56% vs. 98% (p < 0.0001)], Pseudomonas aeruginosa colonized [24% vs. 44% (p = 0.0093)] and needed fewer IV antibiotics [36% vs. 51% (p = 0.041)] than CFclassic. However, a wide spectrum of disease severity was seen amongst CF+RM. CF-patients with a RM cover 6.5% of the Belgian CF-population. Rare mutations can be found in severely ill patients, but more often in late diagnosed, pancreatic sufficient patients.

29 August 2025 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
NMNoelia Rodriguez Mier
Noelia Rodriguez Mier
SCSenne Cuyx
Senne Cuyx
KBKris De Boeck
Kris De Boeck
MPMarijke Proesmans
Marijke Proesmans
MBMieke Boon
Mieke Boon
SVStefanie Vincken
Stefanie Vincken

24 July 2023 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
EWE De Wachter
E De Wachter
JDJc Davies
Jc Davies
NSNj Simmonds
Nj Simmonds
CCCarlo Castellani
Carlo Castellani
KGKm de Winter-De Groot
Km de Winter-De Groot
JBJ Barben
J Barben